Previous 10 | Next 10 |
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10 th Annual SVB Leerink Global He...
KalVista Pharmaceuticals (KALV) announced the closing of its previously announced upsized public offering of 6M shares at a price of $36/share.The closing included the exercise in full by the underwriters of their option to purchase 806K additional shares. Gross proceeds from the offering was...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise i...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks finished modestly higher Friday on light pre-holiday volume following a late-session surge led by the energy sector, as crude oil futu...
KalVista Pharmaceuticals (KALV) prices its upsized public offering of ~5.4M common shares (from 4.5M) at $36.00/share.Expected gross proceeds are $193.5M.Underwriters' over-allotment is an additional ~806.3K shares. Net proceeds will be used to fund clinical trials, continued develo...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting dis...
4 Top Health Care Stocks To Watch This Month Health care stocks have been among the top performers on the stock market this year. Unsurprisingly, this is because we are still facing a global pandemic, and health care has taken center stage. Coupled with waves of new homebound in...
Palm Beach, FL – February 10, 2021 – The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side e...
The biotech industry's a wonky place where the outlook for a company's future can, and often does, change overnight. Successful clinical trial results for a potential drug from KalVista Pharmaceuticals (NASDAQ: KALV) caused its stock price to rocket 114% higher on Tuesday. Investors...
Shares of KalVista Pharmaceuticals (NASDAQ: KALV) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks. KalVista's study showed that 15% of the pat...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...